Research Opportunity: Health LiteracyThere is a new opportunity to participate in a research study about health literacy. Health Literacy Media shares more. We are Health Literacy Media, a non-profit organization based in St... By Editorial TeamMay 6, 2021Bookmark for later Reactions 0 reactions Comments0 comments
U.S. Preventative Services Task Force Issues New Recommendation for Lung Cancer ScreeningThe United States Preventive Services Task Force (USPSTF) has issued 2021 guidelines for lung cancer screening. The last change made to these guidelines was in 2013. A screening test is... By Editorial TeamApril 16, 2021Bookmark for later Reactions 0 reactions Comments5 comments
FDA Approves Cosela™ (trilaciclib) to Reduce Bone Marrow Suppression Caused by ChemotherapyThe U.S. Food and Drug Administration (FDA) has approved Coselsa (trilaciclib) to protect bone marrow from damage caused by chemotherapy. Coselsa is approved for use in adults receiving certain types... By Editorial TeamApril 6, 2021Bookmark for later Reactions 0 reactions Comments0 comments
American Cancer Society Releases 2021 Report on CancerThe American Cancer Society (ACS) has released its 2021 report on cancer, called Cancer Facts and Figures 2021. The data in this report is 2 to 4 years behind the... By Editorial TeamMarch 2, 2021Bookmark for later Reactions 0 reactions Comments1 comments
Tagrisso® (osimertinib) Approved As Adjuvant Therapy for NSCLCThe U.S. Food and Drug Administration (FDA) has granted a new indication (use) for Tagrisso® (osimertinib). The latest indication is for adjuvant therapy after tumor resection (removal) in people with... By Editorial TeamJanuary 7, 2021Bookmark for later Reactions 0 reactions Comments2 comments
COVID-19 Risks for People with CancerEditor’s Note: This article was first published on August 20, 2020. Further developments in what we know about the coronavirus are continuously emerging. Learn more in Self-Care in Uncertain Times... By Editorial TeamAugust 20, 2020Bookmark for later Reactions 0 reactions Comments1 comments
COVID-19 Updates, July 16: Updates on People at Risk, Testing, Reopening, and a VaccineEven after months of navigating life in the COVID-19 era, keeping up with new information and news can be overwhelming. Below are some of the latest developments surrounding COVID-19 for... By Editorial TeamJuly 16, 2020Bookmark for later Reactions 0 reactions Comments0 comments
Zepzelca Approved For Second-Line Treatment Of SCLCThe United States Food and Drug Administration (US FDA) has approved Zepzelca for the treatment of small cell lung cancer (SCLC). Zepzelca (lurbinectedin) is specifically used for adults whose cancer... By Editorial TeamJune 23, 2020Bookmark for later Reactions 0 reactions Comments0 comments
COVID-19 Updates, June 15: Solidarity Hydroxychloroquine Trials and COVID Vaccine DevelopmentMany of us are overwhelmed by the amount of information available on COVID-19. Keeping up with all of the news can be challenging. Here are some of the top developments... By Editorial TeamJune 15, 2020Bookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Alunbrig as a First-Line Treatment for ALK+ Metastatic NSCLCOn May 22, 2020, the U.S. Food and Drug Administration (FDA) approved AlunbrigTM (brigatinib) for adults with ALK+ metastatic non-small cell lung cancer (NSCLC) who had not previously received an... By Editorial TeamMay 26, 2020Bookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLCThe United States Food and Drug Administration (US FDA) has expanded the use of Tecentriq for non-small cell lung cancer (NSCLC). Tecentriq (atezolizumab) has been approved in the past for... By Editorial TeamMay 22, 2020Bookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Opdivo and Yervoy As First Combined Immunotherapy for NSCLCThe United States Food and Drug Administration (US FDA) has approved the use of Opdivo (nivolumab) and Yervoy (ipilimumab) together for non-small cell lung cancer (NSCLC). Opdivo (nivolumab) and Yervoy... By Editorial TeamMay 22, 2020Bookmark for later Reactions 0 reactions Comments0 comments
The Experience In America: Small Cell Lung CancerLung cancer is the second most common cancer in both men and women accounting for 13 percent of all new cancers. Approximately 15 percent of all lung cancers are small... By Editorial TeamMay 21, 2020Bookmark for later Reactions 0 reactions Comments0 comments
COVID-19 Updates, May 7: Remdesivir, Antibody Testing, and Reinfection RiskOur world is still changing every day because of COVID-19. Keeping up with all of the news can be challenging. Here are some of the top COVID-19 updates for people... By Editorial TeamMay 7, 2020Bookmark for later Reactions 0 reactions Comments0 comments
COVID-19 Updates, April 7: Face Coverings, Testing, & MedicationsIt is common to feel overwhelmed about COVID-19: so much information changing day-to-day. Here are some of the important COVID-19 stories that may be applicable to people living with one... By Editorial TeamApril 7, 2020Bookmark for later Reactions 0 reactions Comments1 comments
What to Know About Cancer and COVID-19 (Coronavirus)This article was written on March 31, 2020. Further developments in what we know about the coronavirus are continuously emerging. Learn more in Self-Care in Uncertain Times. The spread of... By Editorial TeamApril 6, 2020Bookmark for later Reactions 0 reactions Comments1 comments
Imfinzi Approved For Extensive-Stage Small-Cell Lung CancerThe United States Food and Drug Administration (US FDA) has approved the drug Imfinzi (durvalumab) for small-cell lung cancer. Imfinzi is specifically for people with small-cell lung cancer that has... By Editorial TeamMarch 31, 2020Bookmark for later Reactions 0 reactions Comments0 comments
(Closed) Take the Fatigue and Health Survey!The 2020 Fatigue and Health survey has now closed. Thank you for your interest! We are excited to share the results with you soon.Exhaustion, tiredness, weariness... fatigue. We know chronic... By Editorial TeamMarch 27, 2020Bookmark for later Reactions 0 reactions Comments0 comments
FDA Grants Breakthrough Therapy Designation to JNJ-6372 in Metastatic Non-Small Cell Lung CancerThe US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a Johnson & Johnson Company. NJ-6372 is an investigational treatment for metastatic non-small... By Editorial TeamMarch 24, 2020Bookmark for later Reactions 0 reactions Comments2 comments
FDA Makes Way for Experimental Drugs to Fight COVID-19On March 19, the U.S. Food and Drug Administration (FDA) approved the testing of two drugs, chloroquine (hydroxychloroquine) and remdesivir, to treat people with COVID-19. The drugs have been given... By Editorial TeamMarch 20, 2020Bookmark for later Reactions 0 reactions Comments3 comments
